一个阶段1b,随机化,开放标签研究,每周一次在2型糖尿病患者中使用胰岛素GZR4
Xuhong Wang1, Ye Hu1, Chengyong Tang2
1Department of Clinical Pharmacology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Diabetes research and clinical practice
|December 20, 2025
概括
GZR4在2型糖尿病患者中证明了安全性和耐受性,其药理动力学特征支持方便的每周一次剂量方案,以改善血糖控制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 2型糖尿病 (T2DM) 管理需要有效和安全的治疗选择.
- 目前的治疗方法通常涉及每日剂量,影响患者的坚持.
- 研究具有改进剂量方便性的新药至关重要.
研究的目的:
- 在T2DM患者中评估GZR4的安全性,耐受性,药理动力学和药理动力学.
- 在1b期试验中,将GZR4的效果与胰岛素降解剂 (IDeg) 进行比较.
- 为了确定GZR4适合于每周一次的使用.
主要方法:
- 一个随机的,主动控制的,1b期试验,涉及T2DM在基础胰岛素的成年人.
- 参与者被随机分配 (3:1) 接受GZR4或IDeg皮下治疗六周.
- 主要终点包括不良事件,严重不良事件和低血糖发生率.
主要成果:
- 低血糖是最常见的治疗出现的不良事件;没有严重的低血糖或SAEs发生.
- GZR4表现出剂量依赖的药理动力学参数,支持每周给药.
- 与IDeg相比,GZR4显示出更大的禁食血葡萄糖 (FPG) 和HbA1c降低.
结论:
- 在T2DM患者中,GZR4是安全的,耐受性良好.
- GZR4的药理动力学和药理动力学特性支持每周一次的剂量计划.
- GZR4为T2DM管理提供了一个有前途的治疗选择,增加了剂量方便性.
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
01:23Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K